Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Considerations for the approach to HRRm testing in prostate cancer

Date

22 Sep 2020

Session

AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Presenters

Alexander Wyatt

Authors

A.W. Wyatt

Author affiliations

  • University of British Columbia, Vancouver/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Chair’s welcome and introductions

Presenter: Neal Shore

Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Resources:

Webcast

Panel discussion

Presenter: Alexander Wyatt

Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Resources:

Webcast

Summary and meeting close

Presenter: Neal Shore

Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.